Evidence map›Paper›PMID 34764853›Full record

ArticleFrontiers in neuroscience2021

Co-grafts of Human Embryonic Stem Cell Derived Retina Organoids and Retinal Pigment Epithelium for Retinal Reconstruction in Immunodeficient Retinal Degenerate Royal College of Surgeons Rats.

Biju B Thomas, Bin Lin, Juan Carlos Martinez-Camarillo, Danhong Zhu, Bryce T McLelland, Gabriel Nistor, Hans S Keirstead, Mark S Humayun, Magdalene J Seiler

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Monitoring Gene Expression in Retina with synthetic serum markers.bioRxiv : the preprint server for biology · 2026
    Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Animal models for the evaluation of retinal stem cell therapies.Progress in retinal and eye research · 2025
    Review
  17. The neuroimmune interface in retinal regeneration.Progress in retinal and eye research · 2025
    Review
  18. Retinal Organoids: Innovative Tools for Understanding Retinal Degeneration.International journal of molecular sciences · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Biju B ThomasDepartment of Ophthalmology, USC Roski Eye Institute, University of Southern California, Los Angeles, CA, United States.
Bin LinDepartment of Physical Medicine and Rehabilitation, University of California, Irvine, Irvine, CA, United States.
Juan Carlos Martinez-CamarilloDepartment of Ophthalmology, USC Roski Eye Institute, University of Southern California, Los Angeles, CA, United States.
Danhong ZhuDepartment of Ophthalmology, USC Roski Eye Institute, University of Southern California, Los Angeles, CA, United States.
Bryce T McLellandDepartment of Physical Medicine and Rehabilitation, University of California, Irvine, Irvine, CA, United States.
Gabriel NistorAIVITA Biomedical Inc., Irvine, CA, United States.
Hans S KeirsteadAIVITA Biomedical Inc., Irvine, CA, United States.
Mark S HumayunDepartment of Ophthalmology, USC Roski Eye Institute, University of Southern California, Los Angeles, CA, United States.
Magdalene J SeilerDepartment of Physical Medicine and Rehabilitation, University of California, Irvine, Irvine, CA, United States.
Southern California Eye Institute · USUniversity of California, Irvine · US

Funding

Ophthalmic Therapeutics Engineering CoreP30EY029220 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Mahnaz Shahidi · 2018 to 2026
$6.5M
Integration and functionality of retinal organoid transplantsR01EY031834 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI SEILER, MAGDALENE J · 2021 to 2025
$3.0M
VRC: A Stem Cell-Based Treatment Strategy for Laser-Induced Permanent Retinal DamagesR01EY031144 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI THOMAS, BIJU BLAVADY · 2019 to 2021
$751k
NEI NIH HHS P30 EY029220NEI NIH HHS R01 EY031144NEI NIH HHS R01 EY031834
6 · The paper itself

Abstract

End-stage age-related macular degeneration (AMD) and retinitis pigmentosa (RP) are two major retinal degenerative (RD) conditions that result in irreversible vision loss. Permanent eye damage can also occur in battlefields or due to accidents. This suggests there is an unmet need for developing effective strategies for treating permanent retinal damages. In previous studies, co-grafted sheets of fetal retina with its retinal pigment epithelium (RPE) have demonstrated vision improvement in rat retinal disease models and in patients, but this has not yet been attempted with stem-cell derived tissue. Here we demonstrate a cellular therapy for irreversible retinal eye injuries using a "total retina patch" consisting of retinal photoreceptor progenitor sheets and healthy RPE cells on an artificial Bruch's membrane (BM). For this, retina organoids (ROs) (cultured in suspension) and polarized RPE sheets (cultured on an ultrathin parylene substrate) were made into a co-graft using bio-adhesives [gelatin, growth factor-reduced matrigel, and medium viscosity (MVG) alginate].

Indexed as

human embryonic stem cells (hESCs)retinal degenerationretinal transplantationtissue engineeringvision testing

Identifiers

PMID34764853
PMCPMC8576198
OpenAlexW3209098613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.